Janux Therapeutics Inc
JANX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.06B
Close$
$-3.69
119.6% downside
Current Fair Value
119.6% downsideOvervalued by 119.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.06 Billion |
|---|---|
| Enterprise Value | $1.09 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.83 |
| Beta | 2.51 |
| Outstanding Shares | 62,937,295 |
Return
| Return on Equity | -15.80% |
|---|---|
| Return on Assets | -14.55% |
| Return on Invested Capital | -17.67% |
Valuation & Multiples
| P/E Ratio | -10.6 |
|---|---|
| PEG | 30.21 |
| Price to Sales | - |
| Price to Book Ratio | 1.35 |
| Enterprise Value to Revenue | 34.15 |
| Enterprise Value to EBIT | -6.5 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$19.07 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$8.03 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7122▼ 20.52% |
|---|---|
| Total Calls | 269,600▼ 40.07% |
| Total Puts | 192,000▼ 53.48% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 98.74%▲ 3.66% |
|---|---|
| Total Invested | $989.02M▲ 19.47% |
| Investors Holding | 204▲ 4.00% |
ESG Score
No data
About Janux Therapeutics Inc
16 employees